Welcome to Scholar Publishing Group

International Journal of World Medicine, 2023, 4(2); doi: 10.38007/IJWM.2023.040207.

Treatment of Vascular Cognitive Impairment: A Bibliometric Analysis over a 12-Year Period


Rui Yang and Shijing Huang

Corresponding Author:
Shijing Huang

Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China


Purpose: The treatment of vascular cognitive impairment is a key point in the field of neuromedicine. Although a lot of research has been carried out, there are few bibliometric studies in this field. This article analyzes the main characteristics of the treatment of vascular cognitive impairment in the past 12 years, and can better contribute to the understanding of the emerging research trends and hotspots related to the treatment of vascular cognitive impairment. Methods: The authors searched for “vascular cognitive impairment” and “treatment” in articles in Web of Science Core Collection database from 2010 to 2022. We analyzed countries, institutions, journals, authors, references, and key words. Through CiteSpace version 6.1.R3 and VOSviewer version 1.6.18, the authors carried on the retrospective bibliometric analysis and draw the atlas. Results: A total of 1923 articles were published from 2010 to 2022. Neurology is the journal with the largest number of citations, while the United States, Capital Med Univ and WANGY are the countries, institutions and authors with the largest number of publications. The research hotspots are cerebral amyloid angiopathy, C-reactive protein, cerebral microvascular disease, blood-brain barrier, white matter lesions, amyloid β-peptide, cholinesterase inhibitors and so on. ConclusionEvery year, more and more articles are published in the treatment of vascular cognitive impairment and great progress has been made. The United States has made the most outstanding contribution in this important area. Cerebral amyloid angiopathy, C-reactive protein, cerebral microvascular disease, blood-brain barrier, white matter lesions, amyloid β-peptide, cholinesterase inhibitors are research hotspots. Neurovascular units, apoptosis, blood-brain barrier, Nf-kb, neuroinflammation may be the frontier of research. The focus of the treatment of vascular cognitive impairment is lifestyle changes, early intervention of vascular risk factors, and improvement of memory function.


Vascular Cognitive Impairment, Treatment, Bibliometric Analysis, CiteSpace, VOSviewer

Cite This Paper

Rui Yang and Shijing Huang. Treatment of Vascular Cognitive Impairment: A Bibliometric Analysis over a 12-Year Period. International Journal of World Medicine (2023), Vol. 4, Issue 2: 48-62. https://doi.org/10.38007/IJWM.2023.040207.


[1] Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, et al. Vascular cognitive impairment and dementia: Jacc scientific expert panel. Journal of the American College of Cardiology. 2019;73:3326-3344

[2] Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials. The Lancet. Neurology. 2007;6:782-792

[3] Devanand DP, Pelton GH, D'Antonio K, Ciarleglio A, Scodes J, Andrews H, et al. Donepezil treatment in patients with depression and cognitive impairment on stable antidepressant treatment: A randomized controlled trial. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2018;26:1050-1060

[4] Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Jr., et al. Recommendations of the 5th canadian consensus conference on the diagnosis and treatment of dementia. Alzheimers Dement. 2020;16:1182-1195

[5] Chen C. Searching for intellectual turning points: Progressive knowledge domain visualization. Proceedings of the National Academy of Sciences of the United States of America. 2004;101 Suppl 1:5303-5310

[6] Chen C, Hu Z, Liu S, Tseng H. Emerging trends in regenerative medicine: A scientometric analysis in citespace. Expert opinion on biological therapy. 2012;12:593-608

[7] Van Eck NJ, Waltman L. Software survey: Vosviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523-538

[8] Liu W, Wong A, Au L, Yang J, Wang Z, Leung EY, et al. Influence of amyloid-β on cognitive decline after stroke/transient ischemic attack: Three-year longitudinal study. Stroke. 2015;46:3074-3080

[9] Zhu Z, Zhang L, Cui Y, Li M, Ren R, Li G, et al. Functional compensation and mechanism of choline acetyltransferase in the treatment of cognitive deficits in aged dementia mice. Neuroscience. 2020;442:41-53

[10] Rajeev V, Fann DY, Dinh QN, Kim HA, De Silva TM, Lai MKP, et al. Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment. Theranostics. 2022;12:1639-1658

[11] Iadecola C. The neurovascular unit coming of age: A journey through neurovascular coupling in health and disease. Neuron. 2017;96:17-42

[12] Iadecola C, Gottesman RF. Neurovascular and cognitive dysfunction in hypertension. Circulation research. 2019;124:1025-1044

[13] Palta P, Carlson MC, Crum RM, Colantuoni E, Sharrett AR, Yasar S, et al. Diabetes and cognitive decline in older adults: The ginkgo evaluation of memory study. The journals of gerontology. Series A, Biological sciences and medical sciences. 2017;73:123-130

[14] Appleton JP, Scutt P, Sprigg N, Bath PM. Hypercholesterolaemia and vascular dementia. Clin Sci (Lond). 2017;131:1561-1578

[15] Cai W, Zhang K, Li P, Zhu L, Xu J, Yang B, et al. Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect. Ageing research reviews. 2017;34:77-87

[16] Zeng W, Chen Y, Zhu Z, Gao S, Xia J, Chen X, et al. Severity of white matter hyperintensities: Lesion patterns, cognition, and microstructural changes. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2020;40:2454-2463

[17] Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: Mild cognitive impairment: Report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology. 2018;90:126-135

[18] Erickson KI, Hillman C, Stillman CM, Ballard RM, Bloodgood B, Conroy DE, et al. Physical activity, cognition, and brain outcomes: A review of the 2018 physical activity guidelines. Medicine and science in sports and exercise. 2019;51:1242-1251

[19] Stillman CM, Cohen J, Lehman ME, Erickson KI. Mediators of physical activity on neurocognitive function: A review at multiple levels of analysis. Frontiers in human neuroscience. 2016;10:626

[20] Clare L, Wu YT, Teale JC, MacLeod C, Matthews F, Brayne C, et al. Potentially modifiable lifestyle factors, cognitive reserve, and cognitive function in later life: A cross-sectional study. PLoS medicine. 2017;14:e1002259

[21] Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42:2672-2713

[22] O'Brien JT, Thomas A. Vascular dementia. The Lancet. 2015;386:1698-1706

[23] Van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, et al. Vascular cognitive impairment. Nat Rev Dis Primers. 2018;4:18003

[24] Román GC, Salloway S, Black SE, Royall DR, Decarli C, Weiner MW, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: Differential effects by hippocampal size. Stroke. 2010;41:1213-1221

[25] Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844-866